An Israeli biomedical company has revealed results from its study on inflammatory pain.
Herzliya-based Cannabotech today announced study results showing an 80 to 100 percent reduction in pain in participants using a cannabinoid-mushroom compound combination.
According to Cannabotech, adding defined concentrations of other cannabinoids allowed them to use less THC to achieve high medical efficacy.
Cannabotech says it expects to launch the treatment in Israel, the United States, and the United Kingdom in the second half of 2022.
The company plans to incorporate the treatment as part of its Integrative Oncology solutions concept with current therapeutic protocols.
Cannabotech says the integration would coincide with conventional chemotherapy and supply physicians with supportive scientific information.
“This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine,” says Cannabotech CEO Elhanan Shaked. “The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment in several cancers, and form part of the Company’s goal to define a new standard for the medical cannabis industry.”
Pain and Treatment
Cannabotech says approximately 50 to 80 percent of cancer patients receive integrative treatment, like herbal products, in addition to chemotherapy.
According to the company, the primary reasons for using integrative products are strengthening the immune system, improving treatment efficacy, and minimizing adverse reactions.
The inflammatory pain study, which utilized a mouse model, focused on Cannabotech’s IntegrativePain product efficacy.
Cannabotech says it intends its products for use in pain reduction from sources like arthritis and chemotherapy.
According to Cannabotech, the uniqueness of its products comes from the ability to achieve high efficacy without high doses of THC or CBD.
Cannabotech says it pairs defined concentrations of cannabinoids like tetrahydrocannabivarin (THCV) and cannabigerol (CBG) to achieve maximum medical efficacy without getting the patient high.
“Pain is the leading indication amongst medical cannabis users,” says Shaked. “However, while most products on the market are inflorescences-based cannabis with high-THC concentrations, Cannabotech presents a different, oil-based concept rich in other active ingredients, whose unique composition shows outstanding results without the unwanted side effects.”
According to Cannabotech, study results showed a significant reduction in pain intensity independent of a direct decreased inflammatory magnitude.
Cannabotech says the decrease suggests that, in addition to their anti-inflammatory actions, the products also affect pain mechanisms.
Like the cannabinoids, Cannabotech says its product’s fungal composition, which includes seven mushroom extracts, demonstrated very high efficacy and impressive pain-relieving properties on its own.
The company’s expectations were met as the fungal and cannabinoid components produced a stronger effect together than individually.
Cannabotech says the result reinforces its claim that treating the endocannabinoid system with cannabinoids jointly with other systems, like the immune system using mushrooms, achieves an increased and more potent medical effect than each of these components individually.
“Pain is one of the central problems the healthcare industry has been attempting to solve for decades,” says Cannabotech pharmacological consultant Dr. Isaac Angel. “Most pain patients’ aches emanate from a combined, partly inflammatory source, which significantly impairs their quality of life. Cannabotech’s products have shown heightened efficiency in the current mouse model. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients.”
Innovating Personal Pain Relief
Cannabotech says its study also focused on the importance of tailoring treatment.
The company says it is developing three formulas for pain treatment.
The first is for inflammation-related pain, the second is for neuropathic pain, the third is for pain from integrated sources.
Cannabotech says its research demonstrated the efficacy of different products on pain and inflammation from varying sources and efficacy variations between products.
According to the company, it is developing a personalization system to help physicians make informed and customized decisions regarding IntegrativePain products.
Cannabotech says IntegrativePain products are part of its Integrative Oncology product series that focuses on treating side effects in cancer and chemotherapy patients.
The company says it expects to conclude its trial, part of a series on all Integrative Oncology products, in the next few months.